Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Non-interventional, Observational, Multi-center Trial to Evaluate Compliance and Efficacy in Mono and Combination Treatment of Candesartan Cilexetil(Atacand)/ Candesartan Cilexetil 16mg, Hydrochlorothiazide 12.5mg(Atacand Plus) in Hypertension

NCT00526279 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00526279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00526279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Non-interventional, Observational, Multi-center Trial to Evaluate Compliance and Efficacy in Mono and Combination Treatment of Candesartan Cilexetil(Atacand)/ Candesartan Cilexetil 16mg, Hydrochlorothiazide 12.5mg(Atacand Plus) in Hypertension
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
June 30, 2007
Completion date
August 31, 2008
Enrollment
9,000 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension